Efficacy and safety of ovine reinforced tissue matrix for ventral hernia repair: a systematic review and meta-analysis.

TL;DR

Systematic review and meta-analysis of OviTex (ovine reinforced tissue matrix) for ventral hernia repair shows significantly lower recurrence rates compared to synthetic or other biologic meshes at mean 19.3-month follow-up. Safety profiles regarding surgical site occurrences and hospital length of stay were comparable between groups.

Key findings

• OviTex demonstrated reduced hernia recurrence rates (RR 0.45; 95% CI 0.22–0.94; p=0.03) compared to synthetic or biologic meshes across 9 studies including 534 patients
• No significant differences in surgical site occurrences or hospital length of stay between OviTex and comparison groups
• Mesh was most commonly placed retromuscularly (39%) or intraperitoneally (35%) with 88% primary fascial closure rate
• Evidence base is limited (only 4 studies in pooled analysis); authors recommend longer follow-up and prospective trials to validate findings

Why this matters at the bedside

OviTex combines biologic and synthetic properties to potentially reduce inflammatory response while maintaining structural support. The reduced recurrence rate could be particularly relevant for patients with risk factors or prior mesh infections, though current evidence remains preliminary and limited to short-term follow-up.